PTPRC
protein-codingprotein tyrosine phosphatase receptor type C, the group of Fibronectin type III domain containing|Protein tyrosine phosphatases receptor type|CD molecules
Gene summary
The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitosis, and oncogenic transformation. This PTP contains an extracellular domain, a single transmembrane segment and two tandem intracytoplasmic catalytic domains, and thus is classified as a receptor type PTP. This PTP has been shown to be an essential regulator of T- and B-cell antigen receptor signaling. It functions through either direct interaction with components of the antigen receptor complexes, or by activating various Src family kinases required for the antigen receptor signaling. This PTP also suppresses JAK kinases, and thus functions as a regulator of cytokine receptor signaling. Alternatively spliced transcripts variants of this gene, which encode distinct isoforms, have been reported. [provided by RefSeq, Jun 2012]
- CD45
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~120.9 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0012163
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0015702
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0012163
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0012163
Submitter: ClinGen
PTPRC was first reported in relation to severe combined immunodeficiency, T cell-negative, B cell-positive, NK cell-positive disease in 2000 (Kung C et al., 2000, PMID:10700239). PTPRC deficiency is an autosomal recessive disease that is usually diagnosed at the time of newborn screening (where applicable) and otherwise the first 6 months of life. If untreated, PTPRC deficiency SCID leads to death usually within the first year. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms (including Candida albicans, Pneumocystis carinii, and cytomegalovirus). It is characterized by failure to thrive (linked to the recurrent infections), normal or elevated numbers of natural killer cells (NK) and peripheral blood B cells, absent or very low peripheral blood T cells (severe T cell lymphopenia) and low or absent immunoglobulins. Patients also present with pancytopenia and decreased T-cell proliferation in response to mitogen. The curation of PTPRC related to autosomal recessive severe combined immunodeficiency with MONDO:0012163 ID (T cell-negative, B cell-positive, NK cell-positive) includes both case-level and experimental evidence. Five variants (one missense, one in-frame indel, one nonsense, one frameshift and one large deletion (that spans over part of PTPRC gene but has unknown size and boundaries)) reported in four probands in four publications (PMIDs: 10700239, 11145714, 22689986 and 26915675) are included in this curation. A score of 6.2 points for genetic evidence has been reached. The mechanism of pathogenicity appears to be loss of function (LOF). This gene-disease association is also supported by animal models, biochemical function and expression assays (PMIDs: 8334701, 8666928, 22724066, 2550143, 7428806, 8943569, 8428589, 1380033 and 28735895). Phenotypes of mice with PTPRC mutations were consistent with patients’ phenotypes, presenting normal or elevated numbers of B cells and low numbers or nearly absent mature T cells. Expression studies of CD45 in bone marrow and lymphoid tissues is consistent with the immunodeficiency associated with CD45 variation (PMID:7428806). Up-regulation of CD45 during positive selection is consistent with the stalling of T-cell maturation at the CD4+ CD8+ double-positive stage observed in patients with SCID due to CD45 variation (PMID: 8943569). CD45 is a phosphatase necessary for the activation of the kinase Lck (PMID: 8428589) that is critically needed to transduce signals downstream of T cell receptor triggering (PMID: 1380033). CD45 modulates Lck by dephosphorylating Tyrosine residues and it was observed that some of these residues and their phosphorylation status play an active part in the interaction between these two proteins (PMID: 28735895). CD45 has a large, heavily glycosylated extracellular domain, and this aspect plays important (and non-enzymatic) roles in activation of T cells and B cells by regulating the physical closeness of cell-surface molecules on antigen presenting cells with counter molecules on T cells. CD45 is alternately spliced upon activation of T cells, which regulates its physical size. A score of 6 points for experimental evidence has been reached, increasing the total score to 12.2 points. In summary, PTPRC is definitively associated with autosomal recessive severe combined immunodeficiency, T cell-negative, B cell-positive, NK cell-positive. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen SCID/CID GCEP on the meeting date December 16, 2021 (SOP Version 8).
Inheritance Pattern: AR
Disease ID:MONDO:0800104
Submitter: PanelApp Australia
Clinical Genomic Database (CGD)
Manifestation: Allergy/Immunology/Infectious
Intervention: Allergy/Immunology/Infectious
Rationale: Antiinfectious prophylaxis and early and aggressive treatment of infections can be beneficial; BMT has been described
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to PTPRC variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_002838.5. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 4 | 381 | 3 | 388 | ||
| missense | 1 | 384 | 31 | 416 | ||
| nonsense | 7 | 1 | 2 | 10 | ||
| start loss | 1 | 1 | ||||
| frameshift | 10 | 2 | 12 | |||
| splice donor/acceptor (+/-2bp) | 1 | 17 | 14 | 32 | ||
| Total | 18 | 21 | 405 | 412 | 3 | 859 |
Highest pathogenic variant AF is 0.000012391635
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_002829.3 | 32 | MANE Select | |
| Ensembl | ENSP00000411355.3 | 32 | MANE Select | |
| RefSeq | NP_001254727.1 | 3 | Standard | |
| RefSeq | NP_563578.2 | 29 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Primary immunodeficiency - Homo sapiens (human)
- Cell adhesion molecules (CAMs) - Homo sapiens (human)
- T cell receptor signaling pathway - Homo sapiens (human)
- Fc gamma R-mediated phagocytosis - Homo sapiens (human)
- JAK-STAT-Ncore
Biological Process
- activation of MAPK activity
- natural killer cell differentiation
- negative regulation of T cell mediated cytotoxicity
- positive regulation of T cell mediated cytotoxicity
- negative regulation of cytokine-mediated signaling pathway
Molecular Function
- protein tyrosine phosphatase activity
- transmembrane receptor protein tyrosine phosphatase activity
- signaling receptor binding
- protein binding
- heparin binding
Cellular Component
- plasma membrane
- integral component of plasma membrane
- focal adhesion
- external side of plasma membrane
- cytoplasmic side of plasma membrane
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000442510
- Coding exons
- 32
- Length
- 118745
- Individuals with no LoFs
- 125705
- Homozygous LoFs
- 1
- Heterozygous LoFs
- 42
- Defined
- 125748
- p
- 0.000171
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 1.17 | 597 | 683 | 0.874 | 0.0000341 | 8660 |
| Missense (PolyPhen) | 171 | 236.39 | 0.72339 | 3048 | ||
| Synonymous | -0.902 | 259 | 241 | 1.07 | 0.0000126 | 2374 |
| Loss of Function | 6.86 | 8 | 69.9 | 0.115 | 0.00000346 | 881 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00012 | 0.00012 | rare |
| Latino/Admixed American | 0.00017 | 0.00017 | rare |
| Ashkenazi Jewish | 0.000099 | 0.000099 | rare |
| East Asian | 0.00049 | 0.00049 | rare |
| Finnish | 0.00014 | 0.00014 | rare |
| European (Non-Finnish) | 0.00011 | 0.00011 | rare |
| South Asian | 0.00033 | 0.00029 | rare |
| Other | 0.00016 | 0.00016 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity (By similarity). {ECO:0000250, ECO:0000269|PubMed:11909961, ECO:0000269|PubMed:2845400}.;
- Disease
- DISEASE: Severe combined immunodeficiency autosomal recessive T- cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]: A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. {ECO:0000269|PubMed:11145714}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Multiple sclerosis (MS) [MIM:126200]: A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheath, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease. {ECO:0000269|PubMed:11101853}. Note=Disease susceptibility may be associated with variations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.670
Intolerance Scores
- RVIS EVS
- 0.23
- RVIS percentile EVS
- 68.57
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- K
- Indispensability pred.
- E
- Indispensability score
- 0.960
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |